Success is defined as alive without aGVHD or cGVHD at day 56 after randomization
| . | Treatment arm, n (%) . | |
|---|---|---|
| Day 56 GVHD-free survival status . | MMF, N = 116 . | Placebo, N = 119 . |
| Success* | 69 (59.5) | 60 (50.4) |
| Failure | 47 (40.5) | 59 (47.8) |
| Died prior to day 56 | 11 (9) | 13 (10.9) |
| Alive with aGVHD | 12 (10.3) | 9 (7.5) |
| Alive with cGVHD | 1 (<1) | 4 (3.3) |
| Alive with systemic drug added or escalation of corticosteroids | 21 (18.1) | 29 (24.3) |
| Lost to follow-up or withdrew consent | 2 (1.7) | 4 (3.3) |
| Total evaluable | 116 | 119 |
| . | Treatment arm, n (%) . | |
|---|---|---|
| Day 56 GVHD-free survival status . | MMF, N = 116 . | Placebo, N = 119 . |
| Success* | 69 (59.5) | 60 (50.4) |
| Failure | 47 (40.5) | 59 (47.8) |
| Died prior to day 56 | 11 (9) | 13 (10.9) |
| Alive with aGVHD | 12 (10.3) | 9 (7.5) |
| Alive with cGVHD | 1 (<1) | 4 (3.3) |
| Alive with systemic drug added or escalation of corticosteroids | 21 (18.1) | 29 (24.3) |
| Lost to follow-up or withdrew consent | 2 (1.7) | 4 (3.3) |
| Total evaluable | 116 | 119 |
P = .16.